CD4 and pneumocystosis: The median duration of secondary prophylaxis for pneumocystosis was significantly shorter for the 145 patients who had early discontinuation of prophylaxis than for the 71 patients who continued prophylaxis until CD4 increased to ≧200 cells/μL (2.7 vs. 4.0 months).